热门资讯> 正文
Acelyrin GAAP EPS—5.43美元
2024-03-29 05:01
- Acelyrin press release (NASDAQ:SLRN): FY GAAP EPS of -$5.43.
- Cash, cash equivalents and short-term marketable securities totaled $721.3 million at December 31, 2023.
-
More on Acelyrin
- Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis
- Acelyrin gains after positive phase 1/2 data for thyroid eye disease drug
- Acelyrin jumps 10% on izokibep psoriatic arthritis results
- Historical earnings data for Acelyrin
- Financial information for Acelyrin
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。